Combination of immunotherapy and other targeted therapies in advanced cutaneous melanoma

References

• Chapman PB, Robert C, Larkin J, Haanen JB, Ribas A, Hogg D, Hamid O, Ascierto PA, Testori A, Lorigan PC, et al. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. Ann Oncol. 2017;28(10):2581–87. doi:https://doi.org/10.1093/annonc/mdx339.
   PubMed Web of Science ®Google Scholar
• Topalian SL. Targeting immune checkpoints in cancer therapy. JAMA. 2017;318(17):1647–48. doi:https://doi.org/10.1001/jama.2017.14155.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):1290. doi:https://doi.org/10.1056/NEJMoa1003466.
   Web of Science ®Google Scholar
• Larkin J, Minor D, D’Angelo S, Neyns B, Smylie M, Miller WH Jr, Gutzmer R, Linette G, Chmielowski B, Lao CD, et al. Overall survival in patients with advanced melanoma who received nivolumab versus investigator’s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial. J Clin Oncol. 2018;36(4):383–90. doi:https://doi.org/10.1200/JCO.2016.71.8023.
   PubMed Web of Science ®Google Scholar
• Gide TN, Wilmott JS, Scolyer RA, Long GV. Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma. Clin Cancer Res. 2018;24(6):1260–70. doi:https://doi.org/10.1158/1078-0432.CCR-17-2267.
   PubMed Web of Science ®Google Scholar
• Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang NAS, Andrews MC, Sharma P, Wang J, Wargo JA, Pe’er D, et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell. 2017;170(6):1120–33. doi:https://doi.org/10.1016/j.cell.2017.07.024.
   PubMed Web of Science ®Google Scholar
• Rotte A, Jin JY. Lemaire V mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. Ann Oncol. 2018;29(1):71–83. doi:https://doi.org/10.1093/annonc/mdx686.
   PubMed Web of Science ®Google Scholar
• Tarhini A. Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica (Cairo). 2013;2013:857519.
   PubMedGoogle Scholar
• Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A, Bahleda R, Hollebecque A. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139–48. doi:https://doi.org/10.1016/j.ejca.2015.11.016.
   PubMed Web of Science ®Google Scholar
• Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res. 2019;38(1):255. doi:https://doi.org/10.1186/s13046-019-1259-z.
   PubMed Web of Science ®Google Scholar
• Weber JS, Gibney G, Sullivan RJ, Sosman JA, Slingluff CL Jr, Lawrence DP, Logan TF, Schuchter LM, Nair S, Fecher L, et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial [published correction appears in Lancet Oncol. 2016 Jul;17 (7): e270]. Lancet Oncol. 2016;17(7):943–55. doi:https://doi.org/10.1016/S1470-2045(16)30126-7.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, Grob -J-J-J-J, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535–46. doi:https://doi.org/10.1056/NEJMoa1910836.
   PubMed Web of Science ®Google Scholar
• D’Angelo SP, Larkin J, Sosman JA, Lebbé C, Brady B, Neyns B, Schmidt H, Hassel JC, Hodi FS, Lorigan P, et al. Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis. J Clin Oncol. 2017;35(2):226–35. doi:https://doi.org/10.1200/JCO.2016.67.9258.
   PubMed Web of Science ®Google Scholar
• Shoushtari AN, Wagstaff J, Ascierto PA, Butler MO, Lao CD, Marquez-Rodas I, Chiarion-Sileni V, Dummer R, Ferrucci PF, Lorigan P, et al. CheckMate 067: long-term outcomes in patients with mucosal melanoma. J Clin Oncol. 2020;38(15_suppl):10019. doi:https://doi.org/10.1200/JCO.2020.38.15_suppl.10019.
   Google Scholar
• Lebbé C, Meyer N, Mortier L, Marquez-Rodas I, Robert C, Rutkowski P, Menzies AM, Eigentler T, Ascierto PA, Smylie M, et al. Evaluation of two dosing regimens for nivolumabin nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIIb/IV CheckMate 511 trial. J Clin Oncol. 2019;37(11):867–75. doi:https://doi.org/10.1200/JCO.18.01998.
   PubMed Web of Science ®Google Scholar
• Cagney DN, Martin AM, Catalano PJ, Redig AJ, Lin NU, Lee EQ, Wen PY, Dunn IF, Bi WL, Weiss SE, et al. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro-Oncology. 2017;19(11):1511–21. doi:https://doi.org/10.1093/neuonc/nox077.
   PubMed Web of Science ®Google Scholar
• Di Giacomo AM, Valente M, Cerase A, Lofiego MF, Piazzini F, Calabrò L, Gambale E, Covre A, Maio M. Immunotherapy of brain metastases: breaking a “dogma.” J Exp Clin Cancer Res. 2019;38(1):419. doi:https://doi.org/10.1186/s13046-019-1426-2.
   PubMed Web of Science ®Google Scholar
• Di Giacomo AM, Ascierto PA, Pilla L, Santinami M, Ferrucci PF, Giannarelli D, Marasco A, Rivoltini L, Simeone E, Nicoletti SV, et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBITM1): NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol. 2012;13(9):879–86. doi:https://doi.org/10.1016/S1470-2045(12)70324-8.
   PubMed Web of Science ®Google Scholar
• Di Giacomo AM, Ascierto PA, Queirolo P, Pilla L, Ridolfi R, Santinami M, Testori A, Simeone E, Guidoboni M, Maurichi A, et al. Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. Ann Oncol. 2015;26(4):798–803. doi:https://doi.org/10.1093/annonc/mdu577.
   PubMed Web of Science ®Google Scholar
• Di Giacomo AM, Chiarion Sileni V, Del Vecchio M, Ferrucci PF, Guida M, Quaglino P, Guidoboni M, Marchetti P, Cutaia O, Amato G, et al. Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: primary analysis of the phase III NIBIT-M2 trial. Ann Oncol. 2020;31:S672–S710. doi:https://doi.org/10.1016/j.annonc.2020.08.1205.
   Web of Science ®Google Scholar
• Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, Khushalani NI, Lewis K, Lao CD, Postow MA, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018;379(8):722–30. doi:https://doi.org/10.1056/NEJMoa1805453.
   PubMed Web of Science ®Google Scholar
• Tawbi HA, Forsyth PAJ, Hodi FS, Lao D, Moschos SJ, Hamid O, Atkins MB, Lewis KD, Thomas RP, Glaspy JA, et al. Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204). J Clin Oncol. 2019;37(15_suppl):9501–950. doi:https://doi.org/10.1200/JCO.2019.37.15_suppl.9501.
   Web of Science ®Google Scholar
• Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, Wilmott JS, Edwards J, Gonzalez M, Scolyer RA, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018;19(5):672–81. doi:https://doi.org/10.1016/S1470-2045(18)30139-6.
   PubMed Web of Science ®Google Scholar
• Long GV, Atkinson VG, Lo S, Sandhu SK, Brown M, Gonzalez M, Guminski A, Scolyer RA, Emmett L, Menzies AM, et al. Long-term outcomes from the randomized phase II study of nivolumab (nivo) or nivo+ ipilimumab nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets): anti-PD1 brain collaboration (ABC). Ann Oncol. 2019;30:v533–v563. doi:https://doi.org/10.1093/annonc/mdz255.001.
   Web of Science ®Google Scholar
• Amaral T, Kiecker F, Schaefer S, Stege H, Kaehler K, Terheyden P, Gesierich A, Gutzmer R, Haferkamp S, Uttikal J, et al. Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients. J Immunother Cancer. 2020;8(1):e000333. doi:https://doi.org/10.1136/jitc-2019-000333.
   PubMed Web of Science ®Google Scholar
• Rulli E, Legramandi L, Salvati L, Mandala M. The impact of targeted therapies and immunotherapy in melanoma brain metastases: a systematic review and meta-analysis. Cancer. 2019;125(21):3776–89. doi:https://doi.org/10.1002/cncr.32375.
   PubMed Web of Science ®Google Scholar
• Huard B, Prigent P, Tournier M, Bruniquel D, Triebel F. CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins. Eur J Immunol. 1995;25(9):2718–21. doi:https://doi.org/10.1002/eji.1830250949.
   PubMed Web of Science ®Google Scholar
• Taube JM, Young GD, McMiller TL, Chen S, Salas JT, Pritchard TS, Xu H, Meeker AK, Fan J, Cheadle C, et al. Differential expression of immune-regulatory genes associated with PD-L1 display in melanoma: implications for PD-1 pathway blockade. Clin Can Res. 2015;21(17):3969–76. doi:https://doi.org/10.1158/1078-0432.CCR-15-0244.
   PubMed Web of Science ®Google Scholar
• He Y, Rivard CJ, Rozeboom L, Yu H, Ellison K, Kowalewski A, Zhou C, Hirsch FR. Lymphocyte-activation gene-3, an important immune checkpoint in cancer. Cancer Sci. 2016;107(9):1193–97. doi:https://doi.org/10.1111/cas.12986.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Bono P, Bhatia S, Melero I, Nyakas MS, Svane I, Larkin J, Gomez-Roca C, Schadendorf D, Dummer R, et al. Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma. Ann Oncol. 2017;28:v605–v649. doi:https://doi.org/10.1093/annonc/mdx440.011.
   Web of Science ®Google Scholar
• Burugu S, Dancsok AR, Nielsen TO. Emerging targets in cancer immunotherapy. Semin Cancer Biol. 2018;52:39–52.
   PubMed Web of Science ®Google Scholar
• Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci. 2016;107(10):1373–79. doi:https://doi.org/10.1111/cas.13027.
   PubMed Web of Science ®Google Scholar
• Jiang H, Rivera-Molina Y, Gomez-Manzano C, Clise-Dwyer K, Bover L, Vence LM, Yuan Y, Lang FF, Toniatti C, Hossain MB, et al. Oncolytic adenovirus and tumor-targeting immune modulatory therapy improve autologous cancer vaccination. Cancer Res. 2017;77(14):3894–907. doi:https://doi.org/10.1158/0008-5472.CAN-17-0468.
   PubMed Web of Science ®Google Scholar
• Andtbacka RHI, Collichio F, Harrington KJ, Middleton MR, Downey G, Ӧhrling K, Kaufman HL. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV III–IV melanoma. J Immunother Cancer. 2019;7(1):145. doi:https://doi.org/10.1186/s40425-019-0623-z.
   PubMed Web of Science ®Google Scholar
• Liu Z, Ravindranathan R, Kalinski P, Guo ZS, Bartlett DL. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nat Commun. 2017;8(1):14754. doi:https://doi.org/10.1038/ncomms14754.
   PubMed Web of Science ®Google Scholar
• Puzanov I, Milhem MM, Minor D, Hamid O, Li A, Chen L, Chastain M, Gorski KS, Anderson A, Chou J, et al. Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma. J Clin Oncol. 2016;34(22):2619–26. doi:https://doi.org/10.1200/JCO.2016.67.1529.
   PubMed Web of Science ®Google Scholar
• Long GV, Dummer R, Andtbacka RH Follow-up analysis of MASTERKEY-265 phase 1b (ph1b) study of talimogene laherparepvec (T-VEC) in combination (combo) with Pembrolizumab (pembro) in patients (pts) with unresectable stage IIIB–IV M1c melanoma (MEL). Presented at: the 2018 SMR International congress; 2018 Oct 24-27; Manchester, EN; 2018.
   Google Scholar
• Murciano-Goroff YR, Warner AB, Wolchok JD. The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Res. 2020;30(6):507–19. doi:https://doi.org/10.1038/s41422-020-0337-2.
   PubMed Web of Science ®Google Scholar
• Segal NH, Logan TF, Hodi FS, McDermott D, Melero I, Hamid O, Schmidt H, Robert C, Chiarion-Sileni V, Ascierto PA, et al. Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody. Clin Cancer Res. 2017;23(8):1929–36. doi:https://doi.org/10.1158/1078-0432.CCR-16-1272.
   PubMed Web of Science ®Google Scholar
• Charych D, Khalili S, Dixit V, Kirk P, Chang T, Langowski J, Rubas W, Doberstein SK, Eldon M, Hoch U, et al. Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy. PLoS One. 2017;12(7):e0179431. doi:https://doi.org/10.1371/journal.pone.0179431.
   PubMed Web of Science ®Google Scholar
• Diab A, Tannir NM, Bentebibel S-ES-E, Hwu P, Papadimitrakopoulou V, Haymaker C, Kluger HM, Gettinger SN, Sznol M, Tykodi SS, et al. Bempegaldesleukin (NKTR-214) plus nivolumab in patients with advanced solid tumors: phase I dose-escalation study of safety, efficacy, and immune activation (PIVOT-02). Cancer Discov. 2020;10(8):1158–73. doi:https://doi.org/10.1158/2159-8290.CD-19-1510.
   PubMed Web of Science ®Google Scholar
• Grzywa TM, Sosnowska A, Matryba P, Rydzynska Z, Jasinski M, Nowis D, Golab J. Myeloid cell-derived arginase in cancer immune response. Front Immunol. 2020;11:938.
   PubMed Web of Science ®Google Scholar
• Labadie BW, Bao R, Luke JJ. Reimagining IDO pathway inhibition in cancer immunotherapy via downstream focus on the tryptophan-kynurenine-aryl tryptophan–kynurenine–aryl hydrocarbon axis. Clin Cancer Res. 2019;25(5):1462–71. doi:https://doi.org/10.1158/1078-0432.CCR-18-2882.
   PubMed Web of Science ®Google Scholar
• Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S, Arance A, Carlino MS, Grob -J-J-J-J, Kim TM, et al. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol. 2019;20(8):1083–97. doi:https://doi.org/10.1016/S1470-2045(19)30274-8.
   PubMed Web of Science ®Google Scholar
• Wang D, Jiang W, Zhu F, Mao X, Agrawal S. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR 9 agonist, for cancer immunotherapy. Int J Oncol. 2018;53:1193–203.
   PubMed Web of Science ®Google Scholar
• Middleton MR, Hoeller C, Michielin O, Robert C, Caramella C, Öhrling K, Hauschild A. Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives. Br J Cancer. 2020;123(6):885–97. doi:https://doi.org/10.1038/s41416-020-0994-4.
   PubMed Web of Science ®Google Scholar
• Haymaker C, Andtbacka RHI, Johnson DB, Shaheen MF, Rahimian S, Chunduru S, Gabrail N, Doolittle G, Puzanov I, Markowitz J, et al. 1083MO Final results from ILLUMINATE-204, a phase I/II trial of intratumoral tilsotolimod in combination with ipilimumab in PD-1 inhibitor refractory advanced melanoma. Ann Oncol. 2020;31:S672–S710. doi:https://doi.org/10.1016/j.annonc.2020.08.1207.
   Web of Science ®Google Scholar
• Milhem MM, Long GV, Hoimes CJ, Amin A, Lao CD, Conry RM, Hunt J, Daniels GA, Almubarak M, Shaheen MF, et al. Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy. J Clin Oncol. 2019;37(15_suppl):9534. doi:https://doi.org/10.1200/JCO.2019.37.15_suppl.9534.
   Web of Science ®Google Scholar
• Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867–76. doi:https://doi.org/10.1056/NEJMoa1408868.
   PubMed Web of Science ®Google Scholar
• Long GV, Stroyakovskiy D, Gogas H, Levchenko E, De Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371(20):1877–88. doi:https://doi.org/10.1056/NEJMoa1406037.
   PubMed Web of Science ®Google Scholar
• Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30–39. doi:https://doi.org/10.1056/NEJMoa1412690.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Dummer R. Immunological effects of BRAF+MEK inhibition. Onco Targets Ther. 2018;7:e1468955.
   Google Scholar
• Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, Ferrone CR, Flaherty KT, Lawrence DP, Fisher DE, et al. Selective BRAFV600E BRAF V600E inhibition enhances T cell T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 2010;70(13):5213. doi:https://doi.org/10.1158/0008-5472.CAN-10-0118.
   PubMed Web of Science ®Google Scholar
• Sapkota B, Hill CE, Pollack BP. Vemurafenib enhances MHC induction in BRAF V600E homozygous melanoma cells. Oncoimmunology. 2013;2(1):e22890. doi:https://doi.org/10.4161/onci.22890.
   PubMed Web of Science ®Google Scholar
• Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, Mitra D, Boni A, Newton LP, Liu C, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013;19(5):1225–12231. doi:https://doi.org/10.1158/1078-0432.CCR-12-1630.
   PubMed Web of Science ®Google Scholar
• Donia M, Fagone P, Nicoletti F, Andersen RS, Høgdall E, Straten PT, Andersen MH, Svane IM. BRAF inhibition improves tumor recognition by the immune system: potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer. Oncoimmunology. 2012;1(9):1476. doi:https://doi.org/10.4161/onci.21940.
   PubMed Web of Science ®Google Scholar
• Long GV, Wilmott JS, Haydu LE, Tembe V, Sharma R, Rizos H, Thompson JF, Howle J, Scolyer RA, Kefford RF. Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression. Pigment Cell Melanoma Res. 2013;26(4):499–508. doi:https://doi.org/10.1111/pcmr.12098.
   PubMed Web of Science ®Google Scholar
• Comin-Anduix B, Chodon T, Sazegar H, Matsunaga D, Mock S, Jalil J, Escuin-Ordinas H, Chmielowski B, Koya RC, Ribas A. The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin Cancer Res. 2010;16(24):6040–48. doi:https://doi.org/10.1158/1078-0432.CCR-10-1911.
   PubMed Web of Science ®Google Scholar
• Kono M, Dunn IS, Durda PJ, Butera D, Rose LB, Haggerty TJ, Benson EM, Kurnick JT. Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression. Mol Cancer Res. 2006;4(10):779–92. doi:https://doi.org/10.1158/1541-7786.MCR-06-0077.
   PubMed Web of Science ®Google Scholar
• Vella LJ, Pasam A, Dimopoulos N, Andrews M, Knights A, Puaux A-LA-L, Louahed J, Chen W, Woods K, Cebon JS. MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells. Cancer Immunol Res. 2014;2(4):351–60. doi:https://doi.org/10.1158/2326-6066.CIR-13-0181.
   PubMed Web of Science ®Google Scholar
• Deken MA, Gadiot J, Jordanova ES, Lacroix R, Van Gool M, Kroon P, Pineda C, Geukes Foppen MH, Scolyer R, Song J-YJ-Y, et al. Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma. Oncoimmunology. 2016;5(12):e1238557. doi:https://doi.org/10.1080/2162402X.2016.1238557.
   PubMed Web of Science ®Google Scholar
• Hu-Lieskovan S, Mok S, Homet Moreno B, Tsoi J, Robert L, Goedert L, Pinheiro EM, Koya RC, Graeber TG, Comin-Anduix B, et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) BRAF V600E melanoma. Sci Transl Med. 2015;7(279):279ra41. doi:https://doi.org/10.1126/scitranslmed.aaa4691.
   PubMed Web of Science ®Google Scholar
• Ferrucci PF, Di Giacomo AM, Del Vecchio M, Atkinson V, Schmidt H, Schachter J, Queirolo P, Long GV, Stephens R, Svane IM, et al. KEYNOTE-022 international team. KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAFmutant BRAF-mutant melanoma. J Immunother Cancer. 2020;8(2):e001806. doi:https://doi.org/10.1136/jitc-2020-001806.
   PubMed Web of Science ®Google Scholar
• Nathan P, Dummer R, Long GV, Ascierto PA, Tawbi HA, Robert C, Rutkowski P, Leonov O, Dutriaux C, Mandala M, et al. Spartalizumab plus dabrafenib and trametinib in patients with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: results from the randomized part 3 of the Phase III COMBI-I trial. Ann Oncol. 2020;31:S1142–S1215. doi:https://doi.org/10.1016/j.annonc.2020.08.2273.
   Web of Science ®Google Scholar
• Arance AM, Gogas H, Dreno B, Flaherty KT, Demidov L, Stroyakovskiy D, Eroglu Z, Ferrucci PF, Pigozzo J, Rutkowski P, et al. Combination treatment with cobimetinib (C) and atezolizumab (A) vs pembrolizumab (P) in previously untreated patients (pts) with BRAFV600 wild type (wt) advanced melanoma: primary analysis from the phase 3 III IMspire170 trial. Ann Oncol. 2019;30:v851–v934. doi:https://doi.org/10.1093/annonc/mdz394.066.
   Web of Science ®Google Scholar
• Gutzmer R, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, Pereira RP, Eigentler T, Rutkowski P, Demidov L, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;395(10240):1835–44. doi:https://doi.org/10.1016/S0140-6736(20)30934-X.
   PubMed Web of Science ®Google Scholar
• Arance AMF, O’Day SJ, De La Cruz ML, Petrella T, Jamal R, Ny L, Carneiro A, Berrocal A, Márquez-Rodas I, Spreafico A, et al. LBA44 - Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: initial results of LEAP-004. Ann Oncol. 2020;31:S1142–S1215.
   Web of Science ®Google Scholar